Quote | Praxis Precision Medicines Inc. (NASDAQ:PRAX)
Last: | $39.27 |
---|---|
Change Percent: | 0.0% |
Open: | $41.19 |
Close: | $39.27 |
High: | $41.19 |
Low: | $39.12 |
Volume: | 313,671 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
News | Praxis Precision Medicines Inc. (NASDAQ:PRAX)
2024-06-21 14:41:42 ET More on Praxis Precision Medicines Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing Praxis Precision Medicines announces proposed public offering Praxis gains after mid-stage data for epilepsy candidate Seeking Alph...
2024-05-20 14:30:05 ET Piper Sandler analyst issues OVERWEIGHT recommendation for PRAX on May 20, 2024 12:01PM ET. The previous analyst recommendation was Overweight. PRAX was trading at $44.93 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
Message Board Posts | Praxis Precision Medicines Inc. (NASDAQ:PRAX)
Subject | By | Source | When |
---|---|---|---|
Despite Trial Failure Praxis Still Seeks Advancing Essential | ctb | investorshub | 03/03/2023 4:15:45 PM |
News today. | IPO$ | investorshub | 03/03/2023 4:14:25 PM |
Not looking good now. | IPO$ | investorshub | 03/03/2023 4:13:49 PM |
Getting killed this am. | IPO$ | investorshub | 03/03/2023 3:19:59 PM |
FDA phase 2 approval due in next week | IPO$ | investorshub | 03/01/2023 8:31:53 PM |
News, Short Squeeze, Breakout and More Instantly...
Praxis Precision Medicines Inc. Company Name:
PRAX Stock Symbol:
NASDAQ Market:
Praxis Precision Medicines Inc. Website:
2024-05-20 14:30:05 ET Piper Sandler analyst issues OVERWEIGHT recommendation for PRAX on May 20, 2024 12:01PM ET. The previous analyst recommendation was Overweight. PRAX was trading at $44.93 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-05-16 16:30:03 ET Jefferies analyst issues BUY recommendation for PRAX on May 16, 2024 02:01PM ET. The previous analyst recommendation was Buy. PRAX was trading at $45.32 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...